Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
2761-2780 of 3,900 trials

ALN-F1202: Safety Study in Healthy Adults

We are testing a new treatment called ALN-F1202 to see if it is safe and well-tolerated in healthy adults. This study is important for future research on its use in patients.

Hereditary Angioedema1-2 yearsSafety phase (I)Allergology

Congenital Hyperinsulinism: HM15136 Treatment Study

We are evaluating a new treatment for children with congenital hyperinsulinism to see if it is safe and helps reduce low blood sugar events. This study includes children aged 2 years and older.

Congenital Hyperinsulinism≤3 monthsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementEndocrinologyPediatrics

Epithelioid Malignant Pleural Mesothelioma: Atezolizumab and WT1/DC Vaccine

We are studying the safety and effectiveness of adding a new treatment to standard chemotherapy for patients with epithelioid malignant pleural mesothelioma. This trial aims to see if the combination improves treatment outcomes.

Malignant Pleural Mesothelioma6-12 monthsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncologyPulmonology

Advanced Solid Tumors: BGB-58067 Study

We are investigating a new treatment for patients with advanced solid tumors to see how safe it is and how well it works. This study will help us understand its effects on tumor growth.

Advanced Solid Tumors with MTAP DeletionNon-Small Cell Lung CancerCholangiocarcinoma>2 yearsSafety phase (I)Oncology

Ovarian Cancer: Pembrolizumab with Chemotherapy

We are studying a new treatment combining pembrolizumab with chemotherapy for patients with small cell ovarian carcinoma. The goal is to see how well this combination works and to evaluate its safety.

Ovarian Small Cell Carcinoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Oral Arsenic for Low-Risk Myelodysplastic Syndromes

We are studying whether oral arsenic can help patients with low-risk myelodysplastic syndromes who haven't responded to other treatments. The trial aims to assess its safety and effectiveness over 12 weeks.

Low-Risk Myelodysplastic Syndromes>2 yearsSafety phase (I)16-20 visitsNo PlaceboInvestigational MedicinesHematologyOncology

S-ketamine for Severe Acute Brain Injury

We are studying whether S-ketamine can help patients with severe acute brain injuries who have ongoing brain activity issues. The trial also looks at the safety of this treatment and its effects on recovery over six months.

Brain Hemorrhage and Injury>2 yearsMonitoring phase (IV)Standard MedicinesNeurologyOtolaryngology

Multiple Myeloma: JNJ-79635322 Treatment Study

We are exploring a new drug combined with existing therapies for patients with multiple myeloma. The goal is to see if this combination improves treatment outcomes.

Multiple Myeloma>2 yearsSafety phase (I)HematologyOncology

Rhizarthrosis: Autologous Stromal Vascular Fraction Injection

We are studying the safety and effects of an injection using your own stem cells for treating rhizarthrosis. This trial will help us understand its impact on pain and joint function over several months.

Rhizarthrosis (Thumb Arthritis)>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesOrthopedics and TraumatologyRheumatology

CAR-T Cell Therapy: Understanding Extracellular Vesicles

We are studying how extracellular vesicles change before and after CAR-T cell treatment in patients, especially those experiencing neurotoxicity. This research may help improve patient care and treatment outcomes.

CAR T-cell Therapy>2 yearsMonitoring phase (IV)No PlaceboInvestigational MedicinesHematologyInfectious DiseasesOncology

Multiple Myeloma and Knee Surgery: Apixaban Study

We are comparing how the blood thinner Apixaban works in patients with newly diagnosed multiple myeloma and those undergoing knee replacement surgery. This study aims to understand its effects on blood clotting and how it behaves in the body.

Thromboembolism Prophylaxis>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCardiologyHematologyOncology

Rectal Cancer: NanoEcho Imaging Study

We are exploring a new imaging method for examining rectal lymph nodes in healthy volunteers and rectal cancer patients. The goal is to assess safety and improve detection of lymph node involvement.

Rectal Cancer6-12 monthsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Schizophrenia: Biomarkers for Clozapine Response

We are investigating whether specific biomarkers can help predict how well individuals with schizophrenia respond to clozapine. This research may lead to more tailored treatments for those who need them.

Schizophrenia≤3 monthsMonitoring phase (IV)11-15 visitsNo PlaceboStandard MedicinesNeurologyPsychiatry

Pancreatic Cancer: GEMBRAX and FOLFIRINOX Treatment Study

We are exploring a new treatment sequence for patients with locally advanced pancreatic cancer to see if it improves outcomes and tolerability. This study will help us understand its effects on survival and quality of life.

Non-resectable Pancreatic Cancer3-6 monthsEfficacy phase (II)No PlaceboStandard MedicinesGastroenterologyOncology

Hypertrophic Cardiomyopathy: Bisoprolol vs. Verapamil

We are studying the effects of Bisoprolol and Verapamil on symptoms and heart function in patients with non-obstructive hypertrophic cardiomyopathy. Our goal is to see if these treatments can improve exercise capacity and reduce heart rhythm issues.

Non-obstructive Hypertrophic Cardiomyopathy3-6 monthsMonitoring phase (IV)Standard MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Breast Cancer: Trastuzumab-Deruxtecan Treatment Study

We are investigating if switching to a new drug can help patients with HR+ HER2 low metastatic breast cancer who are not responding well to standard therapy. This study aims to find out if this change improves survival and response rates.

Metastatic Breast CancerEfficacy phase (II)No PlaceboInvestigational MedicinesEndocrinologyOncology

Steroid Treatment for Wheezing in Children

We are studying whether a new steroid treatment can help prevent asthma in children who wheezed for the first time after a rhinovirus infection. The trial will also look at the frequency and severity of wheezing episodes over time.

Acute Wheezing/Bronchiolitis1-2 yearsMonitoring phase (IV)≤5 visitsStandard MedicinesCost ReimbursementPartially RemotePediatricsPulmonology

ImmunoPet Imaging in Solid Cancers: 89Zr-DFO-REGN5054

We are studying a new imaging method for adults with solid cancers who are being treated with Cemiplimab. This research aims to understand how effectively this imaging can track treatment progress.

Advanced Solid Tumor>2 yearsSafety phase (I)Oncology

Lower Risk MDS: Luspatercept and EPO Combination Study

We are studying a new treatment combining luspatercept with EPO for patients with lower risk MDS who haven't responded to previous therapies. The goal is to see if this combination helps improve blood counts and reduces the need for blood transfusions.

Myelodysplastic Syndromes>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesHematologyOncology

Inflammatory Bowel Disease: Risankizumab-800CW Imaging Study

We are investigating the safety and effectiveness of a new imaging agent for patients with Inflammatory Bowel Disease. This study aims to improve how we visualize drug targeting and inflammation in the intestines.

Inflammatory Bowel Disease (IBD)1-2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesCost ReimbursementGastroenterologyInfectious Diseases